Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat for Hyperuricosuria and Calcium Oxalate Stones
NCT01077284Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2010
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of febuxostat in nephrolithiasis (3 arms), sponsored by Takeda. Primary endpoint: Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion. Started Feb 2010; status: completed.
02
Drugs
febuxostat
03
Conditions
nephrolithiasis
Beyond the preview
Go deeper on NCT01077284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01077284.